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Edited by Takashi GojoboriAbstract The regulatory mechanism by which GATA-3 sup-
presses IFN-c gene expression was investigated. A reduction of
GATA-3 using RNA interference technology enhanced, whereas
overexpression of GATA-3 suppressed IFN-c mRNA expression.
IL-4 expression was reciprocally aﬀected by GATA-3. GATA-3-
mediated down-regulation of IFN-c was achieved through the
inhibition of its promoter/enhancer activity. Two GATA ele-
ments located in the cis-regulatory elements did not contribute to
the suppression of IFN-c promoter activity, even though they
behaved as binding sites for GATA-3. The eﬀect of GATA-3 on
IFN-c promoter was lost upon removal of the region encom-
passing 257 to 172. Among several transcription factors
putatively interacting with this region, Stat4, which enhanced
IFN-c promoter activity, was down-regulated by GATA-3 at
gene transcription level. Although GATA-3 has the capacity to
interact with the cis-regulatory elements, it suppresses IFN-c
gene transcription via down-regulation of Stat4.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Helper T (Th) cells develop into at least two distinct subsets
with diﬀerent functional capabilities and cytokine proﬁles [1,2].
Among a variety of key molecules governing Th1/Th2 devel-
opment [3,4], GATA-3 has been implicated in Th2 commit-
ment [5–8]. GATA-3 is selectively expressed in Th2 but not
Th1 cells [5,6,9,10]. Transgenic and retroviral expression of
GATA-3 induces a Th2 cytokine proﬁle in Th1 cells [5,6], while
dominant-negative GATA-3 down-regulates Th2 cytokines in
Th2 clones [9]. Transfection analysis has revealed that GATA-
3 enhances the expression of several Th2 cytokine through the* Corresponding author. Fax: +81-3-5685-6608.
E-mail address: smiya@rinshoken.or.jp (S. Miyatake).
Abbreviations: EMSA, electrophoresis mobility shift assay; MFI, mean
ﬂuorescence intensity; PMA, phorbol 12-myristate 13-acetate; shRNA,
short hairpin form siRNA; siRNA, small double stranded interfering
RNA
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kines. In addition, overexpression of GATA-3 in developing
Th1 cells induces an accessible chromatin conﬁguration at the
IL-4 loci which harbor IL-4, IL-13, and IL-5 [11]. These
ﬁndings suggest that GATA-3 allows the expression of Th2
cytokines by functioning as a transcription factor as well as by
modifying the chromatin structure of the IL-4 loci.
GATA-3 not only transactivates Th2 cytokine genes, but also
suppresses Th1 cytokine expression. Ectopic expression of
GATA-3 leads to the inhibition of IFN-c production under
Th1-polarizing conditions [5,7,8]. In contrast, IFN-c produc-
tion in CD4þ T cells of GATA-3-deﬁcient mouse was increased
even under Th2 condition [12]. It has been demonstrated that
the expression of Th1-accelerating molecules, IL-12Rb2 chain
and Stat4, in murine T cells were decreased upon retroviral
introduction of GATA-3 during cellular diﬀerentiation [7,8].
However, it is not known whether the GATA-3-mediated in-
hibition of IFN-c production is due to a direct eﬀect on its
promoter activation pathway or is indirectly regulated by
suppression of the Th1 developmental process.
In the present study, we evaluated the role of GATA-3 in
IFN-c gene transcription, separately from its overall eﬀects
on T helper subset diﬀerentiation, by employing a human T
cell line, Jurkat Tag cells, that express both Th1 and Th2
cytokines upon stimulation. Recently, it was appreciated
that small double-stranded interfering RNAs (siRNA) can
be powerful sequence-speciﬁc catalysts for targeted RNA
destruction by means of an evolutionarily conserved mech-
anism known as RNA interference [13,14]. Development of
an siRNA expression system in mammalian cells [15,16]
enabled us, in this study, to analyze the role of GATA-3 in
human T cells.2. Materials and methods
2.1. Plasmids
Human GATA-3 cDNA was ampliﬁed from total cDNA of human
peripheral blood lymphocytes using a sense-(50-CCCACCGAAAG-
CAAATCATTCAACG) and antisense-(50-TGTGAGCATCGAG-
CAGGGCTCTAAC) PCR primer pair, and cloned into the pEF6/His
expression vector (Invitrogen Corp. Carlsbad, CA, USA). To con-
struct a short hairpin form siRNA (shRNA)-expression vector, sense
and antisense 21-bp siRNA sequence derived from the 30-UTR region
of human GATA-3 cDNA (sense; 50-GTTCTGGGCAATCAGT
GTTAC), combined with the loop sequence (50-ATTACATCAAG
GG) were inserted into the pUC19 vector containing the human U6blished by Elsevier B.V. All rights reserved.
Fig. 1. Eﬀect of GATA-3 shRNA on IFN-c and IL-4 gene expression. (A) Schematic representation of shGATA-3 expression constructs. (B)–(D)
Jurkat Tag cells were transfected with empty pU6i vector or shGATA-3 (20 lg each) twice on day 0 and 2. (B) and (C) On day 4, the expression of
GATA-3 mRNA was analyzed by real-time quantitative PCR (B) and immunoblotting of whole cell lysates with anti-GATA-3 Ab and anti-actin Ab
(C). (D) Cells (2 106/ml) were either left unstimulated or stimulated with 25 nM PMA+1 lM ionomycin for 6 h. The expression of IFN-c and IL-4
mRNA was measured by real-time quantitative PCR. Data are expressed as mRNA abundance normalized to GAPDH expression. (E)–(G) Cells
were transfected with empty pEF vector, or GATA-3 (10 lg each). (E) After 48 h, cells (2 106/ml) were stimulated and the expression of IFN-c and
IL-4 was measured as above. (F) In addition to the introduction of empty vector or GATA-3, cells were co-transfected with IFN-c-EGFP or IL-5-
EGFP plus IL-4-DsRed-2 reporter plasmids (2 lg each). After 48 h, cells (106/ml) were either left unstimulated or stimulated with 25 nM PMA+1
lM ionomycin for 16 h. The promoter activity was determined as the ﬂuorescence of synthetic EGFP and DsRed-2 measured by ﬂow cytometry. (G)
The expression of GATA-3 was analyzed by immunoblotting of whole cell lysates with anti-Xpress Ab.
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the target GATA-3 gene was identiﬁed as a consequence of BLAST
search of the NCBI DNA database. As the reporter constructs, a
varying length of the 50-ﬂanking region of the human IFN-c gene
(347 to þ2, 257 to þ2 and 171 to þ2 relative to the transcription
initiation site), and the promoter region of the human
IL-5 (511 to þ4) and Stat4 (910 to þ49) genes were cloned into the
pEGFP-1 vector (BD Bioscience Clontech, Palo Alto, CA, USA). The
human IL-4 promoter (1105 to þ4) was cloned into the pDsRed-2
vector (BD Bioscience Clontech). The correct sequences of all con-
structs were veriﬁed by sequencing. pRK5-Stat1 and -Stat4 have been
described [18].
2.2. Measurement of mRNA expression in human T cells
Jurkat Tag cells were cultured and transfected as described [19]. To
introduce shRNA-expression vector, the same transfection was re-
peated after a 48 h interval. At 48 h after ﬁnal transfection, cells weretreated with phorbol 12-myristate 13-acetate (PMA) (25 nM) plus
ionomycin (1 lM) for 6 h at 37 C. Total RNA was then extracted and
reverse transcribed using oligo(dT)12-18 primer and ReverTra ACE
(Toyobo, Osaka, Japan). Quantitative real-time RT-PCR was per-
formed using Assays-on-DemandTM Gene Expression Products (Taq-
Man MGB probes) with an ABI prism 7900 sequence detection
system (Applied Biosystems, Foster City, CA, USA). Transcripts of
IFN-c, IL-4, GATA-3, Stat1 and Stat4 were normalized to GAPDH
abundance.2.3. Reporter assay
After 16 h of stimulation, ﬂuorescence of synthetic EGFP and
DsRed-2 in the transfected cells was measured by ﬂow-cytometry.
Quantitative data are expressed as mean ﬂuorescence intensity nor-
malized to the ﬂuorescence of DsRed-Express derived from co-trans-
fected pCMV-DsRed-Express vector (BD Bioscience Clontech).
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Preparation of nuclear and cytoplasmic extracts and electrophoresis
mobility shift assay (EMSA) were performed as described [19] using a
double-stranded oligonucleotide corresponding to the 115 to 83 site
of the human IFN-c gene. For the supershift assay, two anti-GATA-3
Abs (HG3-31 and HG3-35; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA) were used. Immunoblotting against expressed protein
in whole cell lysates was performed using anti-Xpress Ab (Invitrogen),
anti-actin Ab, anti-Stat1 Ab and anti-Stat4 Ab (Santa Cruz Biotech-
nology) as described [19].3. Results and discussion
The ﬁrst experiment was carried out to investigate the role of
GATA-3 in the synthesis of Th1-speciﬁc cytokines by reducing
endogenously expressed GATA-3 protein. For this purpose, a
plasmid carrying shRNA against GATA-3 driven by a human
U6 promoter (shGATA-3; Fig. 1A) was transfected into Jur-
kat Tag cells. As shown in Fig. 1B and C, GATA-3 mRNA
and protein were constitutively expressed in Jurkat Tag cells.
Introduction of shGATA-3 substantially down-regulated the
expression of GATA-3 at the levels of mRNA (Fig. 1B) as well
as protein (Fig. 1C). Jurkat Tag cells signiﬁcantly transcribed
both the IFN-c and IL-4 gene upon stimulation (Fig. 1D).
According to the down-regulation of GATA-3 by shGATA-3,
the inducible expression of IFN-c was enhanced, while that of
IL-4 was reduced, suggesting that IFN-c expression in human
T cells was down-regulated by endogenous GATA-3. The
possibility of non-speciﬁc and toxic eﬀects of shRNA is most
likely to be excluded from these results, because the expression
of actin was not aﬀected by shGATA-3 (Fig. 1C). In addition,
we conﬁrmed in a separate experiment that shRNA against
ﬁreﬂy luciferase gene failed to aﬀect any parameter examined
(data not shown). Consistent with the results obtained by
shGATA-3, the expression of IFN-c was suppressed, whereas
that of IL-4 was enhanced by ectopic expression of GATA-3
(Fig. 1E). These ﬁndings are consistent with other reports
showing that IFN-c-producing capacity was decreased and
increased in GATA-3-overexpressing and -deﬁcient murine T
cells, respectively [7,8,12,20], and further suggest that the
down-regulation of IFN-c by GATA-3 was achieved at
mRNA expression level.
To clarify, whether GATA-3-mediated suppression of IFN-c
is due to the inhibition of gene transcription, the eﬀect of
GATA-3 on promoter/enhancer activity of the human IFN-c
gene was next analyzed using an improved reporter assay
system. The fragment encompassing )347 to +2, which has
been reported to display full promoter activity of the human
IFN-c gene [21] was coupled to the EGFP reporter gene
(IFN-c-EGFP). Human IL-4 promoter was connected to the
DsRed-2 reporter gene (IL-4-DsRed-2). These reporters were
transfected to Jurkat Tag cells and promoter activity of both
Th1 and Th2 speciﬁc cytokines were simultaneously measured
by ﬂow cytometry. The IL-5 promoter was also coupled with
EGFP (IL-5-EGFP). Both IFN-c and IL-4 promoters were
activated upon stimulation (Fig. 1F; top 2 panels). The in-
ducible promoter activity of IFN-c was suppressed, whereas
that of IL-4 was enhanced by overexpression of GATA-3
(Fig. 1F; second panels from top). In IL-4-DsRed-2/IL-5-
EGFP-transfected cells, both inducible IL-4 and IL-5 pro-
moter activity were augmented by GATA-3 (Fig. 1F; bottom
four panels). The transfected GATA-3 protein was properly
expressed in the cells (Fig. 1G). These ﬁndings suggest thatGATA-3 speciﬁcally down-regulates promoter activity of the
human IFN-c gene.
Nevertheless, it has been documented that promoter activ-
ity of the murine IFN-c gene was enhanced by GATA-3 [22].
The reason for the apparent contradiction is not clear, but it
may be due to the diﬀerence in DNA sequence between the
murine and human IFN-c promoter regions, which display
only 72% identity between positions 300 and 1. Two
consensus GATA motifs are present in the regulatory element
(108 to 91-bp) of the human IFN-c gene, with a 9-bp in-
terval (Fig. 2A), though the distal part of the tandem GATA
site was not conserved in the murine promoter. In order to
clarify, whether and how binding of GATA-3 to the tandem
GATA motifs aﬀect IFN-c promoter activity, three mutant
reporter constructs were employed. Distal, proximal and both
GATA motifs of IFN-c-EGFP were mutated in 347/þ
2-d-mut, 347/þ2-p-mut and 347/þ2-dp-mut, respectively
(Fig. 2A; bottom three constructs). Binding activity of
GATA-3 to these mutant promoters was analyzed by EMSA
using an oligonucleotide containing the tandem GATA motifs
(115/83). At least one speciﬁc binding complex was de-
tected with the 115/83 probe (Fig. 2B). This complex
formation was speciﬁcally inhibited by the addition of an
excess amount of the unlabeled self oligonucleotide and
consensus GATA-3 sites in the IL-5 promoter [10] or the
TCRa-enhancer [23] (Fig. 2B; arrow). Furthermore, two
speciﬁc antibodies against GATA-3 (HG3-31 and HG3-35)
formed a supershift complex with this probe, indicating that
this speciﬁc complex was composed of GATA-3. The 115/
83-d-mut oligonucleotide harboring a mutation in the distal
GATA motif inhibited the complex formation less eﬀectively.
Further, no reduction of the speciﬁc complex formation was
achieved by 115/83-p-mut carrying a mutation in the
proximal GATA motif (Fig. 2A and B). A weak and no
speciﬁc complex was detected with distal and proximal
GATA motif-mutated 115/83 oligonucleotide as probes,
respectively (data not shown), suggesting that both GATA
motifs contribute to the speciﬁc GATA-3 binding and that
introduction of a mutation in these motifs, especially the
proximal motif, diminishes the binding of GATA-3 to the cis-
regulatory element of the IFN-c gene.
To determine the functional contribution of the interaction
between GATA-3 and the tandem GATA motifs to IFN-c
promoter activation, IFN-c-EGFP reporter constructs con-
taining a mutation in the GATA motifs were transfected into
Jurkat Tag cells. The inducible IFN-c promoter activity was
weakly reduced, if at all, by a substitution mutation of one or
both of the GATA motifs (Fig. 2C), suggesting that the
binding of GATA-3 to the tandem GATA motifs does not
participate in the suppressive eﬀect of GATA-3 on the pro-
moter activity of the human IFN-c gene.
This situation drove us to identify cis-regulatory elements
contributing to GATA-3-mediated IFN-c promoter down-
regulation. Therefore, we next prepared serial 50 deletion
constructs of the human IFN-c promoter reporter plasmids
(347/þ2). Deletions up to 257-bp from the transcription
initiation site (257/þ2 construct) did not aﬀect the suppres-
sive eﬀect of GATA-3 (Fig. 2D). However, the inhibitory ac-
tivity of GATA-3 was lost upon removal of an 86-bp fragment
of the 257/þ2 construct (171/þ2). These ﬁndings indicate
that the cis-element located between 257 and 172 is nec-
essary for GATA-3-mediated suppression of IFN-c promoter
Fig. 2. Contribution of tandem GATA sites to IFN-c gene transcription. (A) Schematic representation of IFN-c promoter reporter mutants.
Substitution of the GATA sites is indicated by underlines. (B) Nuclear extract of Jurkat Tag cells was analyzed by EMSA using 115/83 IFN-c
oligonucleotide probe in the absence or presence of the indicated unlabeled competing oligonucleotides, antibodies or control IgG. Arrow indicates
speciﬁc GATA-3 binding. (C) and (D) Cells were transfected with the 347/þ2 IFN-c gene promoter or its mutant-driven EGFP reporter vector in
the absence (C) or presence (D) of empty pEF vector or GATA-3. After 48 h, the cells were stimulated and the promoter activity was determined as
described in Fig. 1.
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construct was higher than that of 257/þ2, suggesting the
possible existence of a silencer element in the region between
257 and 172. It is supported by previous reports showing
that a transcription factor, YY1, diminished IFN-c gene
transcription by interacting with the promoter regions, 221
to 217 and 203 to 199 [24,25].
No potential GATA-3 binding site exists in the cis-element
between positions 257 and 172, but this region contains
binding sites for other transcription factors, such as AP-1 [26],
SP-1 [25], Stat1 and Stat4 [26,27] (Fig. 3A). Among them,
Stat4 expression in developing murine Th1 cells was reported
to be suppressed by retroviral introduction of GATA-3 [8].
Therefore, we analyzed whether GATA-3 modulates the ex-
pression of Stat4 in human T cells. As shown in Fig. 3B and C,the mRNA level of Stat4 as well as Stat1 was clearly increased
upon stimulation. The baseline and inducible expression of
Stat4 and Stat1 were augmented by the reduction of endoge-
nous GATA-3 using shRNA (Fig. 3B). In contrast, the ectopic
expression of GATA-3 suppressed the expression level of both
Stat1 and Stat4 (Fig. 3C). The eﬀect of GATA-3 on Stat4 was
further conﬁrmed at gene transcription level using a reporter
assay. The fragment of the human Stat4 gene encompassing
)910 to +49 was coupled to the EGFP reporter gene and its
activity was measured by ﬂow cytometry. Consistent with the
results of mRNA expression, promoter activity of the Stat4
gene was enhanced upon stimulation (Fig. 3D). The baseline
and inducible Stat4 promoter activity were suppressed by the
overexpression of GATA-3 (Fig. 3D). In these experiments,
proper down-regulation and overexpression of GATA-3
Fig. 3. Role of Stat4 in GATA-3-mediated suppression of IFN-c gene expression. (A) The position of the transcription factor binding sites within
257 to 172 of the human IFN-c gene promoter is shown. Two nucleotides in the Stat1/Stat4 binding site indicated by asterisks were changed in the
347/þ2 IFN-c-STAT-mut-EGFP construct. The T was deleted and the G was changed to C. (B) and (C) Cells were transfected with empty pU6i
vector or shGATA-3 (B), or with empty pEF vector or GATA-3 (C) and the expression of Stat1 and Stat4 mRNA was measured after stimulation as
indicated in Fig. 1. (D) and (E) Cells were co-transfected with Stat4 reporter plasmid (D), 347/þ2 IFN-c-EGFP or 347/þ2 IFN-c-STAT-mut-
EGFP (E) (2 lg each) plus empty vector or GATA-3 (10 lg each). After 48 h, the cells were stimulated and the promoter activity was determined as in
Fig. 1. (F) Cells were transfected with empty pRK5 vector, Stat1 or Stat4 (10 lg each). After 48 h, the expression of IFN-c mRNA was measured
after stimulation. (G) Whole cell lysates were analyzed for the expression of Stat1 and Stat4 by immunoblotting. (H) Cells were transfected with the
257/þ2 or 171/þ2 IFN-c gene promoter-driven EGFP vector in the presence of empty pRK5 vector or Stat4. After 48 h, the cells were stimulated
and the promoter activity was determined.
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shown). These ﬁndings are consistent with the previous report
regarding murine Th1 cells [8] and further suggest that the
down-regulation of Stat4 by GATA-3 in human T cells was
achieved at gene transcription level. Many details of the
mechanism through which GATA-3 represses Stat4 promoter
activity remain to be determined.
Stat4 has been implicated in human IFN-c gene transcrip-
tion, especially as a signaling molecule in the IL-12 pathway
[26,28]. Therefore, we evaluated the eﬀect of Stat4 on IFN-c
gene expression. Transcriptional activity of a mutant 347/þ2
IFN-c promoter reporter which lost the binding activity with
Stat4 [27] was lower than that of the wild type construct
(Fig. 3E). This mutant also lost the susceptibility to overex-
pressed GATA-3. Consistent with previous ﬁndings, overex-
pression of Stat4 clearly enhanced inducible IFN-c expression
(Fig. 3F). Stat1, which was also down-regulated by GATA-3
(Fig. 3B and C), failed to aﬀect IFN-c gene expression, even
though it was properly overexpressed (Fig. 3F and G). Toconﬁrm that Stat4 up-regulates IFN-c gene expression through
its binding site, the eﬀect of Stat4 on the activity of two IFN-c
promoter reporter plasmids was examined. As expected, in-
ducible activity of the 256/þ2 IFN-c-EGFP construct, con-
taining the Stat sites, was enhanced by overexpression of Stat4
(Fig. 3H). In contrast, activity of the 171/þ2 construct, in
which the Stat element was truncated, was not aﬀected by
Stat4. These ﬁndings further support the notion that GATA-3
inhibits IFN-c gene transcription via the down-regulation of
Stat4 expression.
Another important regulator of IFN-c gene expression is T-
bet. However, neither a reduction nor overexpression of
GATA-3 aﬀected the expression level of endogenous T-bet
(data not shown), suggesting that Stat4 but not T-bet is in-
volved in the GATA-3-mediated down-regulation of the IFN-
c gene transcription. T-bet may operate independently of
GATA-3 and/or play a more important role in the regulation
of chromatin conformation during commitment to the Th1
lineage.
68 O. Kaminuma et al. / FEBS Letters 570 (2004) 63–68In conclusion, one of the principal mechanisms through
which GATA-3 inhibits IFN-c gene transcription is down-
regulation of Stat4. Direct binding of GATA-3 to its corre-
sponding element in the IFN-c promoter region does not
participate in the suppression of its transcriptional activity.
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